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Voltage-gated sodium channels (NaV) are molecular characteristics of excitable cells.
Their activation, triggered by membrane depolarization, generates transient sodium
currents that initiate action potentials in neurons and muscle cells. Sodium currents were
discovered by Hodgkin and Huxley using the voltage clamp technique and reported in
their landmark series of papers in 1952. It was only in the 1980’s that sodium channel
proteins from excitable membranes were molecularly characterized by Catterall and
his collaborators. Non-excitable cells can also express NaV channels in physiological
conditions as well as in pathological conditions. These NaV channels can sustain
biological roles that are not related to the generation of action potentials. Interestingly,
it is likely that the abnormal expression of NaV in pathological tissues can reflect the
re-expression of a fetal phenotype. This is especially true in epithelial cancer cells for
which these channels have been identified and sodium currents recorded, while it was
not the case for cells from the cognate normal tissues. In cancers, the functional activity
of NaV appeared to be involved in regulating the proliferative, migrative, and invasive
properties of cells. This review is aimed at addressing the non-excitable roles of NaV
channels with a specific emphasis in the regulation of cancer cell biology.
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When Exciting Discoveries Hide Non-excitable Functions
In the mind of every biologist, the voltage-dependent activation of sodium currents, carrying
inward charges, and responsible for membrane depolarization, is critical and is a specificity of
cells characterized as being “excitable,” such as neurons, skeletal, and cardiac muscle cells. This
knowledge on electrophysiology and cellular excitability directly comes from the tremendous work
of Hodgkin and Huxley, co-laureates of the Nobel Prize in Physiology and Medicine with Eccles
in 1963, for their study of the action potential and the ionic mechanisms involved in nerve cell
membrane excitation. Indeed, in a series of studies they published in 1952, they reported the
analysis of action potential in the squid giant axon and showed that electrical signals are initiated
Abbreviations: CAM, cell adhesion molecules; CNS, central nervous system; ECM, extracellular matrix; Ig, immunoglobulin;
INa, sodium currents, LQT, long Q-T syndrome; MMP, matrix metalloproteinases; NaV, Voltage-gated sodium channels;
NaVα, pore-forming α subunit of voltage-gated sodium channels; NaVβ, β subunits of voltage-gated sodium channels; NCX,
sodium-calcium exchanger; NHE, sodium-proton exchanger; PNS, peripheral nervous system; TTX, tetrodotoxin; VSD,
voltage-sensing domain.
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by sodium currents being activated after an initial membrane
depolarization (Hodgkin and Huxley, 1952a,b,c,d,e; Hodgkin
et al., 1952).
Sodium currents (INa) generate the rapid depolarization
phase of the action potential. They are transient and their
fast inactivation occurring within 1–2ms, along with the
delayed activation of voltage-gated potassium currents, allows the
membrane repolarization and the termination of the electrical
signal. While this “sodium activity” was identified and recorded
using voltage-clamp techniques, nothing was known at that
time on the structure and regulation of membrane proteins
responsible for this sodium permeation. The identification,
cloning and purification of voltage-gated sodium channel
proteins (NaV) came almost 30 years later, in the 1980’s thanks
to the works performed in the respective laboratories of Catterall
and of Numa (for review, see Catterall, 2012). These studies,
along with the multiple mutagenesis studies that were performed,
permitted to propose structural models supporting the different
properties of NaV channels (ion selectivity and conductance,
activation, and inactivation) that were more recently clarified
by information obtained from the X-ray diffraction of crystal
structures of two bacterial NaV channels fromArcobacter butzleri
(NavAb) and from Magnetococcus sp. marinus strain MC-1
(NavMs). NavAb structure was studied in a hybrid closed-pore
conformation but with four activated voltage sensors (Payandeh
et al., 2011), then in two potential inactivated states (that aremore
related to the slow inactivation found in vertebrate channels since
bacterial channels do not have the fast inactivation) (Payandeh
et al., 2012), while NavMs was studied in an open conformation
(McCusker et al., 2012).
It is now well-established that, in mammals, voltage-gated
sodium channels are multimeric transmembrane complexes
composed of a large pore-forming α subunit (NaVα) associated
with one or two, identical or different, smaller β subunits (NaVβ)
(Catterall, 2000; Brackenbury and Isom, 2011).
There are nine genes in humans (SCN1A, SCN2A, SCN3A,
SCN4A, SCN5A, SCN8A, SCN9A, SCN10A, and SCN11A) which
encode for nine different NaVα proteins (NaV1.1 to NaV1.9,
respectively). NaVα are sensitive to membrane depolarization
and belong to a single family owing to their high level of
homology (Goldin et al., 2000). These NaVα proteins are all
composed of four homologous domains (I–IV), each containing
six α-helical transmembrane domains (S1–S6) (Noda et al., 1984).
The first four segments (S1–S4) of each domain are proposed to
constitute the voltage-sensing domain (VSD), and the two other
segments separated by the reentrant extracellular P loop (S5-P-
S6) form the pore of the channel (Payandeh et al., 2011). Sodium
currents can be inhibited by many drugs and toxins that interact
with NaVα proteins at different binding sites and the well-
known selective inhibitor is the pore-blocking toxin tetrodotoxin
(TTX) that interacts with amino acid residues controlling Na+
selectivity in the short α-helical segment of the P-loop between S5
and S6 (Noda et al., 1989; Terlau et al., 1991; Heinemann et al.,
1992). While all NaVα can be inhibited by TTX, two families of
channels have been identified as a function of their sensitivity
to TTX: the “TTX-sensitive channels” NaV1.1-1.4, NaV1.6, and
NaV1.7 that can be blocked by nanomolar concentrations, and
the so-called “TTX-resistant channels” NaV1.5, NaV1.8, and
NaV1.9 requiring micromolar concentrations to be blocked.
NaV1.8 channel is the most insensitive as it has a TTX IC50 ≥
50µM (Catterall et al., 2003).
Obviously, the expression and activity of such proteins were
particularly studied in excitable cells and a preferential tissue
distribution was described as following: NaV1.1–1.3 and NaV1.6
being central nervous system (CNS) neuronal channels, NaV1.7–
1.9 being the primary channels of sensory, sympathetic, and
nociceptive neurons of the peripheral nervous system (PNS),
whereas the NaV1.4 channel is recognized to be the primary
skeletal muscle channel and NaV1.5 being the predominant
channel of the cardiac muscle. However, some tissues express
multiple isoforms of the channels at various levels and in specific
subcellular domains at the plasma membrane. For example,
NaV1.5 is the predominant channel expressed in cardiac cells,
proposed to be responsible for the transient sodium current (also
called INaT) responsible for the initial membrane depolarization
during the cardiac action potential. However, other channels,
initially called “non-cardiac channels” have been found to be
expressed in the heart, albeit to a lesser extent than NaV1.5. These
comprise NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.6, NaV1.7,
and NaV1.8 channels (Maier et al., 2004; Haufe et al., 2005a,b;
Marionneau et al., 2005; Gershome et al., 2011; Noujaim et al.,
2012; Yang et al., 2012b). These “non-cardiac” channels have
been proposed to be mainly expressed at T-tubules and at the
lateral membranes of cardiomyocytes (Brette and Orchard, 2006;
Lin et al., 2011) or even in intracardiac neurons participating to
the neural regulation of the cardiac function (Maier et al., 2002;
Verkerk et al., 2012;Westenbroek et al., 2013).While the role and
importance of these non-cardiac channels in the physiological
cardiomyocyte function is not fully characterized, they may be
responsible for a persistent (or late) sodium current (called INaP)
(Biet et al., 2012) and involved in some pathological conditions
leading to arrhythmias (Yang et al., 2012b; Mishra et al., 2015).
Mutations occurring in genes encoding NaVα may lead to
inherited pathologies called “sodium channelopathies.” These
mutations are responsible for genetically dominant neurological,
muscular or cardiac disorders, and have been characterized
by abnormal excitability. The majority of these mutations
cause gain-of-function effects by impairing NaV channel (fast
or slow) inactivation and prolonging the entry of Na+
ions into the cells. This is the case for gain-of-function
mutations of NaV1.5 resulting in a prolonged ventricular
action potential that have been associated with LQT3, a
syndrome characterized by a prolonged Q-T interval on the
electrocardiogram, and responsible for cardiac arrhythmias
(Wang et al., 1995a,b; Keating and Sanguinetti, 2001). Mutations
in NaV1.4 resulting in inactivation impairments have been
associated with skeletal myopathies in apparently opposing
effects such as hyperkalaemic periodic paralysis characterized by
muscular hypoexcitability, or even paramyotonia congenita or
potassium-aggravated myotonia for which patients suffer from
periods of muscular hyperexcitability, with retarded relaxation
and spontaneous firing of action potentials, which can be
followed by hypoexcitability periods (Jurkat-Rott et al., 2010).
These striking differences depend in fact on the proportion
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of non-inactivating channels: while a low proportion of non-
inactivated channels can lead to muscular hyperexcitability, a
high proportion of non-inactivated channels rapidly generates
paralysis (Hayward et al., 1996). Gain-of-function mutations
have been identified in NaV1.7 channels expressed in small-
diameter dorsal root sensory neurons and cause severe
painful neuropathies, such as in erythromelalgia, due to the
hyperpolarization shift of the voltage dependence of activation
or an impaired inactivation (Waxman et al., 2014; Hoeijmakers
et al., 2015). Loss-of-functionmutations have also been identified
in these channels, such as in NaV1.5 in Brugada syndrome,
thus generating arrhythmias due to inhomogeneous electrical
conduction in ventricles (Remme, 2013) or in NaV1.7 causing
rare recessive congenital loss of pain sensation (Cox et al., 2006).
There are five NaVβ subunits, β1, β1B, β2, β3, and β4, which
are encoded by four different genes. Subunits β1 and β1B are
splice variants encoded by the same SCN1B gene (Isom et al.,
1992; Kazen-Gillespie et al., 2000; Qin et al., 2003), while β2 (Isom
et al., 1995), β3 (Morgan et al., 2000), and β4 (Yu et al., 2003)
are encoded by SCN2B, SCN3B, and SCN4B genes, respectively.
All five NaVβ have an extracellular N-terminal region containing
an Immunoglobulin (Ig) domain, homologous to V-type Ig loop
motifs, which is maintained by two conserved cysteine residues.
With the exception of β1B, all NaVβ subunits are transmembrane
proteins that have a single α-helical transmembrane domain and
a short intracellular domain (Brackenbury and Isom, 2011). β1B,
initially called β1A, is due to an alternative splicing retaining
intron three in SCN1B gene. This results in a protein that differs
from β1 by the absence of a C-terminal transmembrane domain
(Qin et al., 2003). Therefore, β1B is the only member of the NaVβ
family to be a soluble and secreted protein (Kazen-Gillespie et al.,
2000; Patino et al., 2011). NaVβ subunits are non-pore forming
proteins that were initially isolated from rat brain along with
NaVα (Messner and Catterall, 1985). From this pioneer work,
they have been proposed to be auxiliary of NaVα, and they were
indeed demonstrated to promote NaVα trafficking to the plasma
membrane as well as modulation of the voltage-dependence of
activation and inactivation, the rate of inactivation, the recovery
from inactivation and the presence of persistent or resurgent
currents (Calhoun and Isom, 2014). They were also reported
to modulate the pharmacology of NaVα, such as the sensitivity
to lidocaine (Lenkowski et al., 2003) or the binding affinity of
some conotoxins (Wilson et al., 2011; Zhang et al., 2013). NaVα
and NaVβ subunits can interact physically. Indeed, β1 and β3
proteins interact with NaVα through non-covalent associations
within both their N- and C-termini (McCormick et al., 1998;
Meadows et al., 2001), while β2 and β4 proteins covalently
interact with NaVα through the formation of a disulfide bond,
thanks to a conserved cysteine residue present in the N-
terminal extracellular Ig loop (Chen et al., 2012; Gilchrist et al.,
2013). Recently, the structures of the extracellular domains of
human β3 and β4 have been solved at the atomic level by X-
ray crystallography bringing new insights on the interactions
and stoichiometry between NaVα and NaVβ, but also between
NaVβ subunits themselves, as β3 was proposed to form trimers
(Gilchrist et al., 2013; Namadurai et al., 2014). Besides this
well-known role in regulating NaVα addressing to the plasma
membrane and activity, NaVβ subunits were proposed to achieve
other cellular functions. Indeed, the presence of an Ig motif
in their extracellular domain suggested a possible role of these
proteins as cis and trans cell adhesion molecules (CAMs), similar
to that of integrins, cadherins, and selectins (Isom and Catterall,
1996; Isom, 2002). β1 and β2 subunits have been demonstrated
to form both trans-homophilic and trans-heterophilic cell-cell
and cell-matrix adhesions, while it is more controversial for β3,
and unclear for β4. These adhesions have been mainly studied
in cells expressing NaVα, such as neurons in which they were
proven to be critical for neurites outgrowth, axonal fasciculation
and interactions with glial cells (O’malley and Isom, 2015).
Several mutations have also been identified in genes encoding
NaVβ, and have been associated with a number of diseases
primarily occurring in excitable tissues, such as epilepsies, cardiac
arrhythmias and sudden death, due to the disturbed modulation
of NaVα and cell excitability (see a recent review O’malley and
Isom, 2015). For example, a missense mutation in the SCN4B
gene, resulting in the L1759F amino acid substitution in the
β4 protein, has been associated with LQT10. This mutation
induces a gain-of-function of NaV1.5, with a depolarizing shift
of the voltage-dependence of inactivation, therefore leading to
an increased window current and an increased INaP (Medeiros-
Domingo et al., 2007).
Thus mutations or altered expression of NaVβ could lead
to pathologies due to the regulation of NaVα functioning.
Alternatively, the possibility cannot be excluded that pathologies
could arise from NaVβ cell adhesion properties per se.
Besides these relatively well-characterized functions of NaV
channels in excitable cells, multiple studies have demonstrated
the functional expression of NaVα in normal non-excitable
cells, such as in macroglial cells [astrocytes (Sontheimer and
Waxman, 1992), oligodendrocytes (Tong et al., 2009), Schwann
cells (Chiu et al., 1984)], in immune cells [microglia (Korotzer
and Cotman, 1992; Craner et al., 2005), dendritic cells (Kis-
Toth et al., 2011), macrophages (Carrithers et al., 2007, 2009),
T-lymphocytes (Decoursey et al., 1985; Fraser et al., 2004)],
endothelial cells (Traub et al., 1999; Andrikopoulos et al., 2011),
osteoblasts (Black et al., 1995), odontoblasts (Allard et al.,
2006), chondrocytes (Sugimoto et al., 1996), keratinocytes (Zhao
et al., 2008), and fibroblasts (Chatelier et al., 2012). While their
physiological roles were not clearly demonstrated so far, they
were proposed to regulate cellular functions such as survival
or proliferation, cell migration, cell differentiation, endosome
acidification, phagocytosis, and podosome formation. This was
recently reviewed by Black and Waxman and referred to as the
“non-canonical roles” of NaV (Black and Waxman, 2013). As
such, it becomes clearer that NaVα may have developmental
and physiological roles that have been underestimated for long
and while being associated to channel activities and sodium
permeation, are not linked to the generation of action potentials.
This naturally raises the questions on the mechanisms by which
NaV channels fulfill their physiological roles, and how the
voltage-dependence could represent a selective advantage in non-
excitable cells.
Another aspect of interest is the “abnormal” expression
of NaV channels in non-excitable cancer cells, and especially
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in carcinoma cells. This new interest originates from studies
in human and rodent cell lines and biopsies, in which both
NaVα and NaVβ have been reported and sodium currents were
recorded. The abnormal expression of NaVα and NaVβ proteins
and particularly the activity of NaVα in carcinoma cells were
very often, if not always, associated with aggressive features, and
it is tempting to consider cancer as a (sodium) channelopathy.
In this article, we wish to review the present knowledge on
the expression of NaVα and NaVβ in cancer cells and discuss
the possible mechanisms by which this gain-of-function could
regulate oncogenic properties in comparison with their roles in
non-excitable cells.
Expression of Voltage-Gated Sodium
Channels in Cancer Cells: The Potential for
an Action in Oncogenic Properties
Cancers, which are most of the time sporadic genetic diseases,
are among the leading causes of death in the world. The most
common cancers are carcinomas, originating from epithelial
tissues, such as lung, breast, prostate, cervix or colon cancers,
and are responsible for the highmortality by cancer (Parkin et al.,
2005). While cancers differs in their incidence and mortality rate,
depending on the organs in which the primary tumor appears,
the cancer disease is always the result of mutual interactions
between cancer cells from the tumor and the host organism.
As such, the disease and its progression are consequences of
very complex interplays between cancer cells and non-cancer
cells (Hanahan and Weinberg, 2000). Obviously, the promoter
of such a situation is the cancer cell itself, having accumulated
multiple genomic mutations and having survived, as in the
Darwinian principle of evolution, despite the high pressure of
selection in the environment. Indeed, selected cancer cells have
gained proliferative advantages since they had to resist to cell
death, to escape the immune system control, to thrive under the
paucity of stimulating growth factors or despite the existence of
dampening signaling pathways, to survive to episodes of O2 and
nutrients deprivation, etc. According to this stringent process,
the vast majority of cancer cells are dying, but those that are
surviving to environmental constraints have been selected on the
basis of transcriptional modulations that conferred immortality,
growth and invasion advantages. This leads to the well-known
phenotype of cancer cells that have been defined, by Hanahan
and Weinberg, as the acquisition of eight biological capacities:
self-sufficiency for proliferative signaling, insensitivity to anti-
growth signals, resistance to apoptosis, replicative immortality,
energy metabolism adapted to hypoxia, stealth to immune
detection and destruction, induction of tumor angiogenesis,
activated extracellular matrix invasion, and metastasis (Hanahan
and Weinberg, 2011). Therefore, the selected cancer cells are
the most fitted to the drastic environment and definitely the
most aggressive, because of the repression of some growth-
limiting genes and the overexpression of some other genes that
are definitely associated with aggressiveness. Except in the small
proportion of cases for which there are mutations in initiation
genes (such as in BRCA1 for example), the genes that are
deregulated in cancer cells are not different from those found
in normal cells. The signaling pathways that are regulated by the
deregulated genes should be seen as misappropriations by cancer
cells of physiologically regulated functions. These functions could
have been already described or may still be unknown. In this
idea, the carcinogenetic process is very often compared with
conditions such as embryonic development and tissue repairing,
with the ultimate difference that these latter processes are fully
controlled and are always ended-up by cell differentiation.
Over the last two decades, numerous studies have reported
the abnormal overexpression, or underexpression, of some
ion channels in cancer cells, as compared with corresponding
non-cancer cells. Because plasma membrane ion channels are
transmembrane proteins that generate ion fluxes, they are key
regulators of ion homeostasis, membrane potential, cell volume,
and intracellular signaling events. Their abnormal function was
found to regulate several cancer cell biological processes, such
as cell proliferation, resistance to apoptosis, cell adhesion, cancer
cell motility, or extracellular matrix invasion (Schwab and Stock,
2014; Litan and Langhans, 2015). As such some ion channels
were proposed to represent the “hallmarks of cancer cells”
(Prevarskaya et al., 2010). This is certainly the case for NaV
proteins which have been reported to be highly overexpressed in
cancer biopsies and cancer cells while they are undetectable in
most cognate normal tissues (see Table 1) and proposed to serve
as new targets for cancer therapy (Roger et al., 2006).
Pore-forming Navα Proteins in Cancer Cells
The first descriptions of voltage-dependent sodium currents,
and therefore of the functional expression of NaVα proteins at
the plasma membrane of cancer cells, and the hypotheses that
they could participate in the oncogenic process came in the late
1980’s. In these pioneer works voltage-gated sodium currents
were initially recorded in human leukemia cells (Yamashita et al.,
1987; Lee et al., 1988), then in human small-cell lung cancer cells
(Pancrazio et al., 1989). Initial works performed in leukemia cells
were aimed at studying the participation of plasma membrane
conductances in the acquisition of the multidrug resistance
(MDR) phenotype that is a major problem leading to loss of
efficacy of cancer chemotherapy, often associated with a gain
of aggressiveness. In the first of this two studies, two human
leukemia cell lines were characterized at the electrophysiological
level, the drug-sensitive K562 and the adriamycin-resistant cell
line K562/ADM that was selected on the basis of its resistance to
multiple drugs including anthracyclines and Vinca alkaloids. In
contrast to K652 cells which only showed K+ outward currents,
most of the K562/ADM cells also exhibited fast inward voltage-
gated sodium currents that were fully inhibited by 1µM TTX.
Moreover, sodium currents were no longer observed in revertant
cells coming from the K562/ADM cell line having a reduced
MDR phenotype after being grown for 6 months in absence
of adriamycin. While TTX had no effect on cell growth or on
vincristine uptake in K562/ADM cells, these authors concluded
that TTX-sensitive Nav was associated with, albeit not directly
involved in, drug resistance (Yamashita et al., 1987). In the second
study, the drug-sensitive human T-cell leukemia cell line CCRF-
CEM was compared to its MDR variant, vinblastine-resistant
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TABLE 1 | List of the non-nervous tissue cancers in which NaVα have been studied.
Tissues Cancer/
Non-cancer
Cell lines or
biopsies
mRNA
Expression
Protein in
cell line or
biopsies
TTX
sensitivity
Functional
expression
NaVα Role NaVα in biopsies References
Prostate Cancer Biopsies NaV1.8 Yes (IH); staining for
NaV1.8 correlated with
Gleason score: very low
in normal epithelium, low
in moderately aggressive
stages, strong in highly
aggressive cancer with
appearance of staining in
nucleus
Suy et al., 2012
PC-3 NaV1.2
NaV1.3
NaV1.7
NaV1.1
NaV1.2
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
8.6 nM nNaV1.7 Invasion Motility
(galvanotaxis) Motility
(wound healing)
Laniado et al.,
1997; Diss
et al., 2001;
Abdul and
Hoosein, 2002;
Suy et al., 2012
22Rv1 NaV1.1
NaV1.2
NaV1.5
NaV1.6
NaV1.8
NaV1.9
Suy et al., 2012
DU-145 NaV1.1
NaV1.2
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
Suy et al., 2012
LnCaP NaV1.2 NaV1.1
NaV1.2
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
No current Laniado et al.,
1997; Diss
et al., 2001;
Suy et al., 2012
Mat-Ly-Lu
(rat)
NaV1.1
NaV1.4
NaV1.7
18 nM nNaV1.7 Invasion
(galvanotaxis) Motility
(wound healing)
Grimes et al.,
1995; Grimes
and Djamgoz,
1998; Diss
et al., 2001
AT-2 (rat) NaV1.1
NaV1.4
NaV1.9
No current — — Grimes et al.,
1995; Diss
et al., 2001
Non-Cancer PNT2
(normal,
immortalized)
? No current — — Mycielska and
Djamgoz, 2004
Breast Cancer Biopsies NaV1.5
NaV1.6
NaV1.7
Yes (IH, RT-PCR) Fraser et al.,
2005
MDA-MB-
231
fNaV1.5
NaV1.6
NaV1.7
∼2µM nNaV1.5 In vitro invasion
Extracellular
acidification through
allosteric
enhancement of
NHE1 activity;
Yes (RT-PCR) Roger et al.,
2003; Fraser
et al., 2005;
Brisson et al.,
2011, 2013;
(Continued)
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TABLE 1 | Continued
Tissues Cancer/
Non-cancer
Cell lines or
biopsies
mRNA
Expression
Protein in
cell line or
biopsies
TTX
sensitivity
Functional
expression
NaVα Role NaVα in biopsies References
promotion of
proteolytic
invadopodial activity
Promotion of
metastasis in
immunodeficient
mice
Driffort et al.,
2014; Nelson
et al., 2015
MCF-7 NaV1.5
NaV1.6
NaV1.7
No current — — Roger et al.,
2003
MDA-MB-
468
? No current Roger et al.,
2003
Lung Small-cell
lung cancer
H146 ? 215 nM Current ? ? Pancrazio et al.,
1989; Blandino
et al., 1995
H128 ? ? Current ? ? Pancrazio et al.,
1989
H69 NaV1.3
NaV1.5
NaV1.6
TTX-S Current Endocytosis ? Pancrazio et al.,
1989; Onganer
and Djamgoz,
2005
H209 NaV1.3
NaV1.5
NaV1.6
TTX-S Endocytosis ? Onganer and
Djamgoz, 2005
H510 NaV1.3
NaV1.5
NaV1.6
NaV1.9
TTX-S Endocytosis ? Onganer and
Djamgoz, 2005
Non-small cell
lung cancer
H460 NaV1.3
NaV1.5
NaV1.6
NaV1.7
∼10 nM NaV1.7 Invasion Roger et al.,
2007; Campbell
et al., 2013
Calu-1 NaV1.1
NaV1.2
NaV1.3
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
∼5 nM +
∼1µM
NaV1.1
NaV1.2
NaV1.3
NaV1.5
NaV1.6
NaV1.7
Invasion Roger et al.,
2007
H23 NaV1.5
NaV1.6
NaV1.7
∼10 nM NaV1.6
NaV1.7
Invasion Roger et al.,
2007
A549 NaV1.6
NaV1.7
No current — — Roger et al.,
2007
Non-cancer NL20
(normal,
immortalized)
NaV1.2
NaV1.3
NaV1.6
NaV1.7
No current — — Roger et al.,
2007
BEAS-2B
(normal,
immortalized)
NaV1.1
NaV1.5
NaV1.6
NaV1.7
No current — — Roger et al.,
2007
(Continued)
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TABLE 1 | Continued
Tissues Cancer/
Non-cancer
Cell lines or
biopsies
mRNA
Expression
Protein in
cell line or
biopsies
TTX
sensitivity
Functional
expression
NaVα Role NaVα in biopsies References
Leukocytes Leukemia K562 ? ? Current (type
not
identified)
? ? Schlichter et al.,
1986
K562 No current — — Yamashita
et al., 1987
K562/ADM ? <100 nM Current (type
not
identified)
? ? Yamashita
et al., 1987
CCRF-CEM ? <150 nM Current (type
not
identified)
? ? Lee et al., 1988
CEM/VLB100 ? <150 nM Current (type
not
identified)
? ? Lee et al., 1988
Jurkat
(normal,
immortalized)
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
∼900 nM NaV1.5
NaV1.7
invasion Fraser et al.,
2004
Normal Normal
human
lymphocytes
Current (type
not
identified) in
three cells
out of 90
Cahalan et al.,
1985
Primary-
cultured
human
monocytes-
derived
macrophages
NaV1.5
NaV1.6
NaV1.5 (IH)
NaV1.6 (IH)
TTX-R NaV1.5;
protein
localized in
late
endosomes
Phagocytosis,
acidification of
endosomes
Carrithers et al.,
2007
Pleura Mesothelioma Primary-
cultured
human
malignant
pleural
mesothelioma
cells
NaV1.2
NaV1.3
NaV1.4
NaV1.5
NaV1.6
NaV1.7
TTX-
sensitive
current
Increases in vitro
motility
Fulgenzi et al.,
2006
Normal
mesothelial
cells
(Normal,
immortalized)
No current Fulgenzi et al.,
2006
Cervix Cancer Primary-
cultured
human
cervical
carcinoma
cells
NaV1.1
NaV1.2
NaV1.3
NaV1.4
NaV1.6
NaV1.7a
NaV1.7b
NaV1.6 (IH)
NaV1.7 (IH)
TTX-
sensitive
current
NaV1.6-dependent
invasion
Diaz et al., 2007
Non-cancer (Biopsies of
normal
uterine
cervix)
NaV1.1
(very low)
NaV1.2
NaV1.3
NaV1.4
NaV1.6
NaV1.6 (IH)
NaV1.7 (IH)
Diaz et al., 2007
(Continued)
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TABLE 1 | Continued
Tissues Cancer/
Non-cancer
Cell lines or
biopsies
mRNA
Expression
Protein in
cell line or
biopsies
TTX
sensitivity
Functional
expression
NaVα Role NaVα in biopsies References
(very low)
NaV1.7a
NaV1.7b
(very low)
Colon Cancer Biopsies NaV1.5 (IH) House et al.,
2010
HT-29 NaV1.5 (IH) Current NaV1.5-dependent
invasion (shown with
30µM TTX or siRNA)
House et al.,
2010
SW620 NaV1.5 (IH) Current NaV1.5-dependent
invasion (shown with
30µM TTX or siRNA)
House et al.,
2010
SW480 NaV1.5 (IH) Current NaV1.5-dependent
invasion (shown with
30µM TTX or siRNA)
House et al.,
2010
Non-cancer (Biopsies of
normal
colon)
NaV1.5 faint
staining (IH)
House et al.,
2010
Ovary Cancer Anglne NaV1.1
NaV1.2
NaV1.3
NaV1.4
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
NaV1.5 (IH) — Gao et al., 2010
Caov-3 NaV1.1
NaV1.2
NaV1.3
NaV1.4
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
NaV1.5 (IH) TTX-R migration and
invasion
Gao et al., 2010
SKOV-3 NaV1.1
NaV1.2
NaV1.3
NaV1.4
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
NaV1.5 (IH) TTX-R migration and
invasion
Gao et al., 2010
Non-cancer (Biopsies of
normal
ovary)
NaV1.1
NaV1.2
NaV1.3
NaV1.4
NaV1.5
NaV1.6
NaV1.7
NaV1.8
NaV1.9
NaV1.5 (IH) Yes (RT-PCR) Gao et al., 2010
(Continued)
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TABLE 1 | Continued
Tissues Cancer/
Non-cancer
Cell lines or
biopsies
mRNA
Expression
Protein in
cell line or
biopsies
TTX
sensitivity
Functional
expression
NaVα Role NaVα in biopsies References
Primary-
cultured
luteinized
cells of the
granulosa
NaV (type
not
indicated)
(RT-PCR)
NaVα
protein
(type non
identified)
detected
with
panNaVα
antibody
(WB, IH)
6.8 nM TTX-S
current
Physiological
luteolysis of normal
corpus luteum cells
of the ovary
Bulling et al.,
1999, 2000
IH, immune-histochemical staining; nNaV , neonatal isoform; ?, not reported; —, not found.
CEM/VLB100. In both cell lines, an identical TTX-sensitive INa
was found, suggesting a similar level of expression of NaVα
proteins. Furthermore, 1µMTTX did not affect the proliferation
of CCRF-CEM and CEM/VLB100 cells, while it fully inhibited
INa, and the role of this conductance remained unidentified (Lee
et al., 1988). The channels responsible for these TTX-sensitive
sodium currents werenot characterized at that time, and it was
not possible to know whether only one or multiple NaVα were
expressed, and whether these were the same NaVα proteins in all
leukemia cell types.
Later on, INa were recorded in human H146, H69, and
H128 small-cell lung cancer cell lines. These currents were
most probably due to TTX-sensitive channels since they fully
inhibited by 5µM TTX, and while their biological role was not
assessed, they were proposed to participate to a “neuroendocrine-
like” tumor cell phenotype (Pancrazio et al., 1989). This initial
study, along with subsequent works conducted in different labs,
were probably at the origin of the hypothesis defended by
Djamgoz and his team, discussing for a “neuroscience” approach
in oncology (Onganer et al., 2005). During the following two
decades, between the 1990’s and the 2010’s, the idea came that
cancer cells, originating from different non-excitable tissues,
acquired membrane excitability that would be associated with
cancer progression. However, the existence of such action
potentials, being either spontaneous or triggered, in carcinoma
cells is still questioned. This “excitability” hypothesis is discussed
hereafter, and while it is not the one that we are supporting,
it could have appeared a tempting proposal with regard to
the well-known role of NaV in excitable cells. Djamgoz and
researchers from his team brought an important contribution to
the field of NaV channels in cancer. Many of their studies clearly
showed the expression of functional NaVα proteins in cancer
cells, as in rat (Grimes et al., 1995; Grimes and Djamgoz, 1998)
and human (Laniado et al., 1997) prostate cancer cells, T-cell
leukemia (Fraser et al., 2004), human small-cell lung cancer cells
(Onganer and Djamgoz, 2005), and more recently proposed it as
a therapeutic target in ovarian cancer cells (Frede et al., 2013).
From the very beginning, the presence of INa was associated with
the enhanced migration and the invasive phenotype of cancer
cells (Smith et al., 1998; Djamgoz et al., 2001; Fraser et al., 2003),
while the cellular mechanisms proposed to be involved remained
elusive until recent studies (Brisson et al., 2011, 2013; Yang et al.,
2012a).
In their first study, they recorded INa in the highly invasive
and metastatic Mat-Ly-Lu, but not in the weakly invasive AT-
2, rat prostate cancer cells. Sodium currents were fully inhibited
by 1µM TTX, suggesting the expression of TTX-sensitive NaVα
proteins at the plasmamembrane of prostate cancer cells (Grimes
et al., 1995). In Mat-Ly-Lu cell line, TTX was not interfering
with cancer cell proliferation but reduced by about 33% cancer
cell invasiveness through an invasion chamber coated with
an extracellular matrix composed of Matrigel™. In contrast,
TTX had no effect on the invasiveness of AT-2 cells. Later
on, similar results were obtained in human prostate cancer
cells: TTX-sensitive INa was recorded in highly invasive PC-
3 cells and its pharmacological inhibition significantly reduced
cell invasiveness, while no current was observed in the weakly
invasive LNCaP cells (Laniado et al., 1997). In these two
studies performed with prostate cancer cell lines, while INa
was only recorded in highly invasive cells PC-3 or Mat-
Ly-Lu, it appeared that the expression of NaVα seemed to
be restricted to a subpopulation of cells since INa was not
recorded in all investigated cells. This particularity was further
studied in different human and rat prostate cancer cell lines by
flow cytometry using a fluorescein-labeled polyclonal Pan-Nav
antibody, and the authors found a positive correlation between
the proportion of cells expressing NaVα at the plasma membrane
and the invasive capacity (Smith et al., 1998).
Following these studies, the NaVα protein responsible for
TTX-sensitive currents in prostate cancer cells was investigated,
and from this attempt came confusing results that however
demonstrate that the NaVα isoform expressed per semight not be
critical for the biological effect in cancer cells. Indeed, the study
from Diss and collaborators indicated that the mRNA encoding
the full-length skeletal muscle type 1 (SkM1), now identified as
being NaV1.4, was present in the Mat-Ly-Lu cell line and also
expressed in the PC-3 cells. In situ hybridization suggested that
NaV1.4 transcripts were expressed in both Mat-Ly-Lu and AT-2
cells but with a markedly different expression level since highly
invasive Mat-Ly-Lu and PC-3 cells exhibited much higher levels
(Diss et al., 1998). These results indicated (1) that NaV1.4 mRNA
could be expressed in other cells than skeletal muscle cells, and
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(2) that the expression level of NaV1.4 mRNA seemed to be
associated with the invasive capacities of cancer cells, known to
express functional NaVα. Here is the origin of the confusion:
while authors of this study never concluded that NaV1.4 was
responsible for INa in highly invasive prostate cancer cells, the
inferred association might have been formulated in the mind of
many researchers.
After this study, Bennett and collaborators compared the
expression of Pan-NaVα proteins by immunoblotting in the
weakly invasive LNCaP human prostate cancer cells, and two
derivative cell lines, C4 and C4-2, which present increasing
invasive properties. They found a positive correlation between
NaVα expression and the increased invasiveness of cancer cell
lines, and that the use of TTX (1µM) reduced thematrix invasion
by these three cell lines to the same level (Bennett et al., 2004).
Also of interest is the fact that the transient overexpression
of NaV1.4 proteins in cancer cells increased their invasiveness.
These results perfectly fitted with the initial study from Diss et al.
(1998) and it was proposed that NaV1.4 expression was sufficient
to increase prostate cancer cell invasiveness. However, by using
degenerate primer screening and semi-quantitative PCR, it was
later found that PC-3 and Mat-Ly-Lu cells express mRNA for
NaV1.4, but also for NaV1.1 and NaV1.2 channels and that
the predominant isoform was the TTX-sensitive NaV1.7. This
channel was likely to be responsible for INa in prostate cancer
cells (Diss et al., 2001). NaV1.7 was found to be overexpressed,
in mRNA and in proteins, in prostate cancer biopsies compared
to non-cancer prostate tissues, and it was even proposed to serve
as a diagnosis marker for prostate cancer (Diss et al., 2005).
These results demonstrated that, even if NaV1.7 might be the
channel primarily overexpressed and involved in the invasive
properties of prostate cancer cells, the mechanisms responsible
for enhancing cancer cell invasiveness can be reproduced by
the overexpression of another NaVα. This is very important
because it suggests that the activity of NaVα, i.e., INa, might be
more important than the molecular identity of the channel, and
that broad spectrum inhibitors of NaV rather than some being
very specific to isoforms, could be used to reduce cancer cell
invasiveness.
In breast cancers, it appeared that the most expressed was
NaV1.5 (Fraser et al., 2005; Gillet et al., 2009). In the strongly
metastatic MDA-MB-231 human breast cancer cell line, all tested
cells express voltage-gated sodium currents. These currents were
initially found to be TTX-resistant, with an IC50 of approximately
2µM and required 30µM TTX to be fully inhibited. This
current was not recorded in weakly invasive MCF-7 or MDA-
MB-468 breast cancer cells, nor in non-cancerous MCF-10A
epithelial mammary cells (Roger et al., 2003; Brisson et al.,
2011). Its pharmacological inhibition, using the pore-blocker
TTX (Roger et al., 2003; Gillet et al., 2009; Brisson et al.,
2011), the antiarrhythmic ranolazine (Driffort et al., 2014), or
the antiepileptic phenytoin (Yang et al., 2012a) had no effect on
MDA-MB-231 cell proliferation, nor on cell migration through a
non-coated filter with 8-µm-diameter pores, but reduced by 30
to 40% the invasion through the same filters coated with a film
of Matrigel™ as an extracellular matrix. While MDA-MB-231
cells express mRNA for multiple NaVα such as NaV1.2, NaV1.4,
and NaV1.8 at low level, and NaV1.5, NaV1.6, and NaV1.7 at
high levels (Jude et al., 2006), only NaV1.5 seemed active at the
plasma membrane. Targeting SCN5A expression using specific
siRNA completely abolished the presence of INa and had the same
effect as TTX for reducing cancer cell invasiveness. Conversely,
increasing the activity of NaV1.5 channels using veratridine
increased cancer cell invasiveness (Gillet et al., 2009). This
channel was found to be expressed as a neonatal splice variant,
called nNaV1.5, showing seven amino acids substitutions in the
second extracellular loop (E2) of the first domain (DI) of the
channel compared to the adult isoform (aNaV1.5) (Fraser et al.,
2005; Brackenbury et al., 2007). This molecular domain is critical
for NaV pharmacology and neonatal isoforms display functional
and pharmacological specificities, such as the sensitivity to some
other drugs such as verapamil and diltiazem, but not nifedipine
(Roger et al., 2004b). NaV1.5 was found to be overexpressed
in breast cancer biopsies compared to non-cancerous biopsies,
associated with lymph node invasion, metastatic relapse and a
decreased survival in patients (Fraser et al., 2005; Yang et al.,
2012a).
In a human leukemia model, it was found by patch-clamp
recordings that a subpopulation of approximately 10% of Jurkat
T cells was expressing TTX-resistant sodium currents, with
an IC50 around 1µM. The expression of NaVα proteins was
confirmed by western blotting using a Pan-NaV antibody. Semi-
quantitative PCR analyses revealed the expression of mRNAs
for multiple NaVα such as NaV1.7 (TTX-sensitive) and NaV1.9
(TTX-resistant) at low levels, and NaV1.5 (TTX-resistant) and
NaV1.6 (TTX-sensitive) at much higher levels. Correlatively
to the pharmacology of the sodium current recorded it was
proposed that the channel most likely to be functional was
NaV1.5. Inhibiting the current with 10µM TTX reduced Jurkat
cell invasiveness through Matrigel™-coated inserts by more than
90% (Fraser et al., 2004).
In human non-small-cell lung cancer cell lines it was found
that the strongly metastatic H23, H460 and Calu-1 cancer cells
possessed INa while the weakly invasive A549 and the non-cancer
lung epithelial cells NL-20 and BEAS-2B did not. The presence of
INa was associated with a significant increase in the intracellular
concentration of Na+ in cancer cells (15.3 ± 2.2mM) compared
to non-cancer cells (7.8 ± 1.3mM). Again, the inhibition of
these sodium currents, using different concentrations of TTX
had no effect on cancer cell proliferation or on cell migration,
but reduced cancer cell invasiveness through an extracellular
matrix by about 50% (Roger et al., 2007). However, the NaVα
channels likely to be responsible for this activity in the three
studied cell lines might be different. Indeed, while the TTX
sensitivity of sodium currents recorded in H23 and H460 cells
was in the nanomolar range, and therefore considered as being
TTX-sensitive, in Calu-1 cells it appeared that there were two
populations of currents, one being TTX-sensitive and one being
TTX-resistant. The use of TTX at different concentrations
to partially inhibit TTX-S (5 nM), fully inhibit TTX-S and
partially TTX-R (1µM) or fully inhibit all channels (30µM)
produced dose-dependent reductions of Calu-1 invasiveness.
It was concluded that both types of NaVα, TTX-S and TTX-
R, were equally involved in the invasive properties, and that
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only the activity was important. Surprisingly, semi-quantitative
RT-PCR experiments indicated that all the studied cell lines,
cancerous and non-cancerous, expressed mRNA for NaVα, and
especially for the TTX-S NaV1.6 and NaV1.7. In the case of
H23 and H460 cells, NaV1.7 mRNA was the most abundant
and was proposed to be responsible for INa (Roger et al., 2007).
This was later confirmed in H460 cancer cells, where using
specific siRNA targeting NaV1.7 to inhibit its expression led to
a decrease in invasiveness, and in weakly invasive A549 cells
where transfection to force the expression of the channel was
responsible for an increased invasiveness (Campbell et al., 2013).
Interestingly, H23 and H460 cells also expressed mRNA for
NaV1.5, but the TTX sensitivity of INasuggested that it was
not functionally expressed. Calu-1 cells expressed mRNA for
all NaVα, except for NaV1.4. The particular pharmacology of
the current along with kinetics of activation and inactivation
indicated the TTX-R channel likely to be functional at the
plasma membrane might be NaV1.5, while the TTX-S current
could be due to NaV1.1, NaV1.3, NaV1.6, and/or even NaV1.7
activity (Roger et al., 2007). Of interest is the fact that poorly
aggressive A549 cells expressed NaVα proteins in intracellular
compartments but not at the plasma membrane, and that
TTX (30µM) applied extracellularly (but possibly endocytosed),
induced no effect on cell invasiveness. This suggests that NaV
activity at the plasma membrane is critical for inducing matrix
invasion. In this study, it was surprising to notice that non-
cancer cells, NL-20 and BEAS-2B, also expressed mRNA for
NaV1.6, NaV1.7, plus NaV1.5 for the latter, had NaVα proteins as
observed in western blotting experiments, but that these proteins
seemed to be incorrectly matured and not addressed at the
plasmamembrane (Roger et al., 2007). These cells are non-cancer
cells and non-tumorigenic when injected to immunodepressed
mice. However, they cannot be considered as being normal, since
they have been immortalized and might bear some mutations.
Therefore, it is tempting to speculate that functional expression
of NaVα at the plasma membrane is a feature of highly invasive
cancer cells withmultiple mutations accumulated, while themere
expression of NaVα mRNA/protein might be deregulated at the
earlier stages of the carcinogenic process.
In human colon cancer cell lines SW620, SW480, and HT29,
the expression of mRNA was identified for several NaVα,
with the most abundant transcripts being those encoding the
TTX-R NaV1.5. In these three cell lines, the presence of the
NaV1.5 proteins at the plasma membrane was confirmed by
immunocytochemistry, and their functionality was identified
by measuring TTX-R INa (partially inhibited by 10µM TTX)
in patch-clamp recordings (House et al., 2010). Here again,
the use of TTX (30µM in order to inhibit >70% of sodium
current) or siRNA specifically targeting NaV1.5 expression,
induced a significant reduction of cancer cell invasiveness, by
approximately 50%, compared with untreated or non-sense
control siRNA-treated cells. SW620 cells were shown to express
both adult and neonatal NaV1.5 splice variants. Increasing the
activity of the channels with veratridine (10µM) promoted
cancer cell invasiveness, while inhibiting them using the local
anesthetics lidocaine (10µM) or ropivacaine (2.5µM) had
opposite effects (Baptista-Hon et al., 2014). The presence of
NaV1.5 proteins at the plasma membrane of the luminal surface
of cancer cells was confirmed by immunohistochemistry in a
panel of human colon cancer specimens. By comparison, normal-
matched control samples showed very faint or no staining.
This suggested that functional expression of NaV1.5 might be
repressed in normal tissues but that they are aberrantly expressed
in colon cancer cells (House et al., 2010). In the same study,
authors also used a powerful bioinformatics approach combining
transcriptomic analyses and invasion experiments in order to
identify networks of invasion-related genes, the expression of
which could be regulated by, or related to, NaV1.5 expression in
colon cancer cells (House et al., 2010).
A recent study assessed the mRNA expression of NaV1.6
channels (SCN8A gene) using real-time quantitative PCR in
colorectal carcinomas (n = 64 patients). A significantly lower
expression of SCN8A was found in colorectal tumor tissues
compared to paired tumor-surrounding non-cancerous tissues,
and in patients below the age of 45 compared to older patients.
Of all the other patient parameters evaluated as a function of
SCN8A expression, such as gender, tumor grade, tumor location
(cecum vs. right colon) and histopathological classification, there
was no significant relationship (Igci et al., 2015). However, the
significance of such findings remains unclear since the expression
of other NaVα was not assessed, it is not indicated whether
the transcript evaluated was an adult or a neonatal variant.
Furthermore, NaV1.6 protein expression and activity were not
evaluated.
The team of Gomora demonstrated the functional expression
of TTX-sensitive NaVα in primary cultures established from
human cervical cancer biopsies. By using RT-PCR and specific
primers they looked for the expression of the TTX-sensitive
NaV1.2, NaV1.4, NaV1.6, and NaV1.7 channels which were all
amplified in cervical cancers while only mRNA for NaV1.4 were
identified in normal cervix tissues (Diaz et al., 2007). Another
study from the same group indicated that mRNA levels of
NaV1.6 were approximately 40-fold higher in cervical cancer
biopsies than in non-cancerous cervical tissues, and that NaV1.7
mRNA expression was also increased approximately 20-fold in
cancer tissues. Moreover, immunohistochemistry experiments
demonstrated that both NaV1.6 and NaV1.7 proteins were
significantly more expressed in cancer biopsies and in primary
culture of cancer cells compared to non-cancer tissues, and
widely distributed in both cytosolic and plasma membrane
compartments. The activity of NaV1.6 channels in the plasma
membrane of cervical cancer cells was confirmed using the
NaV1.6-specific toxin Cn2 (1µM) which blocked ∼50% of
the sodium current in patch-clamp experiments, and reduced
by ∼20% cell invasiveness of primary-cultured cervical cancer
cells, without affecting cell proliferation or migration. TTX
(1µM) had a similar effect on cancer cell invasiveness
(Hernandez-Plata et al., 2012).
The expression of NaVα was also assessed in human ovarian
cancer cell lines and in ovarian cancer biopsies, which were
compared with normal ovary samples. The relative mRNA
expression, analyzed by RT-PCR, was found higher for NaV1.1,
NaV1.3, NaV1.4, and NaV1.5 in ovarian cancers cells compared
with normal ovarian tissues, and the mRNA expression of
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NaV1.2, NaV1.4, NaV1.5, and Nav1.7 was also significantly
increased in highly invasive ovarian cancer cells Caov-3 and
SKOV-3, compared with the weakly invasive Anglne ovarian
cancer cells, while the expression of mRNA for other NaVα
was not significantly different. The expression of mRNA and
proteins forNaV1.5 seemed to be increased in cancer tissues and
seemed to be correlated with the grade and metastasis status of
ovarian cancers. In vitro, the treatment of Caov-3 and SKOV-
3 cells with 30µM TTX reduced cell invasiveness by 50–60%,
while 1µM TTX had no effect. The authors suggested that the
abnormal expression of NaV1.5 could be associated with the
metastatic process in human ovarian cancer and could be used
as a therapeutic target in ovarian cancer treatment (Gao et al.,
2010).
From all these studies it appears that several NaVα such as
NaV1.5, NaV1.6, and NaV1.7 have been unequivocally shown to
be abnormally expressed and functional in different cancer types.
The reason why these particular channels are overexpressed
in cancers, and the transcriptional deregulations responsible
for this are not known and might be tissue-specific. However,
as previously suggested, the molecular identity of the channel
might not be very important as long as a sodium current
exists at the plasma membrane. While these currents could
be recorded in experimental conditions ensuring for a large
current, i.e., using the patch-clamp technique, and performing
a highly depolarized voltage step (such as −10 or 0mV) from
a very hyperpolarized membrane potential (−100 or −120mV),
a question rapidly appeared in this context: how could these
channels be functional in cancer cells for which the membrane
potential is rather depolarized compared to excitable cells (Yang
and Brackenbury, 2013) and generally comprised between −40
and −30mV (Roger et al., 2003, 2004a,c, 2007; Gillet et al.,
2009, 2011)? Indeed, the relatively depolarized membrane
potential reported in cancer cells would significantly decrease
the availability of NaV and would preclude for action potential
initiation.
When looking at the activation-voltage and inactivation-
voltage relationships of these channels, it was demonstrated that
a window of voltage always existed, in which channels can be
activated and not fully activated, and that the mean membrane
potential of the studied cancer cells was within this window
of voltage (Roger et al., 2003, 2004a, 2007; Fraser et al., 2004;
Diaz et al., 2007; Gillet et al., 2009; Campbell et al., 2013). This
suggested that NaVα could be functional, through a window
current that could be considered as being a “basal activation” of
channels. This small but persistent entry of sodium into cancer
cells is likely to be responsible for the increase in intracellular
sodium content that has been demonstrated a long time ago
in cancer tissues compared to non-cancer tissues (Cameron
et al., 1980). The relationships between the increased intracellular
concentration of Na+ and the enhancement of cancer cell
invasiveness are still very unclear and will be discussed in the
following part of this review.
Even though mechanistic details on the participation of NaV
to the invasive properties of cancer cells remain incomplete,
it became very promising to search for ways to decrease the
expression of such channels in cancer cells, or alternatively to
inhibit their activity in order to reduce metastatic colonization
of organs. Recent studies clearly demonstrated that the
pharmacological inhibition of NaVα was very potent to prevent
the development of metastases in rodent models, such as the
use of TTX (Yildirim et al., 2012), phenytoin (Nelson et al.,
2015), or ranolazine (Driffort et al., 2014). Another way to
regulate the aggressivity of breast cancer cells could be the
transcriptional inhibition of NaV1.5 expression in breast cancer
cells by n-3 polyunsaturated long chain fatty acids coming
from the diet, such as docosahexaenoic acid (C22:6n-3) (Isbilen
et al., 2006; Gillet et al., 2011), that was recently identified
as being mediated by the lipid-sensitive transcription factor
Peroxisome Proliferator Activated Receptor (PPAR)-β (Wannous
et al., 2015).
Non Pore-Forming NaVβ Proteins in Cancer Cells
The participation of non-pore-forming NaVβ in oncogenic
processes was not studied as much as that of NaVα, but it
becomes more and more obvious that they could play important
roles during carcinogenesis and cancer progression toward high
metastatic grades. The most studied NaVβ protein in cancer is
β1, which results from the expression of the SCN1B gene. Initial
studies indicated that β1 expression was high in poorly invasive
MCF-7 breast cancer cells and lower in highly invasive MDA-
MB-231 breast cancer cells in vitro. However, the participation
of β1 in the invasive phenotype was not very clear. In weakly
invasive MCF-7 cells, which do not express functional NaVα, the
transfection of siRNA targeting β1 reduced cell adhesion by 35%,
and increased cell migration by about 120%. Its overexpression
in highly invasive MDA-MB-231 cells, endogenously expressing
functional NaV1.5, increased cell process length and adhesion,
and reduced lateral motility and cell proliferation (Chioni et al.,
2009). Surprisingly, the overexpression of β1 increased the
activity of the pro-invasive sodium channel, which, expectedly,
should have increased cell invasiveness. These results suggested
that β1 expression could prevent cancer cell invasion. In a recent
study, it was nicely demonstrated that SCN1B mRNA and β1
proteins were up-regulated in breast cancer biopsies, compared
with non-cancer breast samples. MDA-MB-231 overexpressing
β1 were significantly more invasive than untransfected control
cells, through both NaVα-dependent and NaVα-independent
mechanisms, and generated bigger primary tumors, more and
bigger metastatic foci, when implanted into the mammary fat
pads of immunosuppressed Rag2−/− and Il2rg−/− mice (Nelson
et al., 2014). The overexpression of β1 seemed to increase primary
tumor vascularization and to reduce cancer cell apoptosis.
β1-over expressing cancer cells also displayed an elongated
morphology, with the formation of cellular process outgrowths
requiring the activity of Fyn kinase, and NaV1.5 current (Nelson
et al., 2014). Consistently with this, SCN1B mRNA was found
to be more abundant in highly invasive than in weakly invasive
prostate cancer cell lines (Diss et al., 2008).
Not many studies have been focused on the potential
participation of the β2 subunit in cancer cell properties. This
subunit is similar to neural CAMs and is known to form both
homotypic and heterotypic interactions with several CAMs,
among which the β1 subunit (Isom et al., 1995; Malhotra
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et al., 2000). Subunit β2 interacts with glycoproteins from
the ECM such as Tenascin-C and Tenascin-R (Srinivasan
et al., 1998; Xiao et al., 1999) which are important factors
regulating physiological cell proliferation and migration during
embryogenesis, particularly in neurogenic areas (Midwood et al.,
2011; Anlar and Gunel-Ozcan, 2012), but also cancer cell
proliferation and migration (Brellier and Chiquet-Ehrismann,
2012). Therefore, it was initially postulated that the increased
expression of β2 in cancer cells could promote cancer
progression. It was initially observed that β2 was overexpressed
in the metastatic prostate cancer cell subline C4-2B compared to
the weakly metastatic mother cell line LNCaP from which it is
derived (Jansson et al., 2012). Furthermore, the overexpression of
the β2 protein, bearing a GFP tag at the intracellular C-terminus,
induced a change in LNCaP cell morphology with the acquisition
of a bipolar and elongated phenotype. This was also accompanied
by an increase in cell adhesion to vitronectin and Matrigel™,
but not to growth factor-reduced Matrigel™ or to fibronectin,
and the increase in cell migration and in Matrigel™ invasion,
with no significant effect on cell proliferation. In contrast to
what could have been initially expected, the overexpression
of β2 in LNCaP reduced the growth of the xenogenic tumor
generated by subcutaneous injection of cells in balb/c nude mice
(Jansson et al., 2012). Later on, the same group demonstrated in
organotypic spinal cord co-cultures, that LNCaP prostate cancer
cells overexpressing β2 displayed an enhanced association with
nerve axons (Jansson et al., 2014). It also increased cancer cell
migration, invasion and proliferation on laminin, suggesting
that the overexpression of β2 in prostate cancer cells may
be involved in metastatic perineural invasion (Jansson et al.,
2014).
While the role of β3 in cancer cell biology is uncertain, it
is of interest to notice that two missense mutations have been
identified in the SCN3B gene in high grade metastatic colorectal
cancer biopsies (Sjoblom et al., 2006), and that non-mutated
SCN3B gene was proposed to induce apoptosis through a p53-
dependent signaling pathway in cancer cells after DNA damages
(Adachi et al., 2004). The SCN3B gene is not expressed at all in
highly invasive MDA-MB-231 breast cancer cells (Gillet et al.,
2009) and is found at very low level in non-small-cell lung cancer
cells (Roger et al., 2007; Campbell et al., 2013). In contrast,
SCN3B expression was increased in cervical cancer biopsies
when compared to non-cancer samples (Hernandez-Plata et al.,
2012). In the same study, SCN2B and SCN4B expression was
decreased in cervical cancer biopsies (Hernandez-Plata et al.,
2012). SCN4B expression appeared to be very low in invasive
breast cancer cells (Gillet et al., 2009), and decreased in invasive
compared to non-invasive prostate cancer cells (Diss et al.,
2008).
These results suggest that NaVβ may be involved in cancer
cell biology. However, other studies are necessary to clearly
establish their respective and complementary roles in cancer
cell properties such as cell proliferation and resistance to
apoptosis, cell adhesion, migration and extracellular matrix
invasion. It will also be important to determine whether
these properties are dependent, or not, on the expression
of NaVα.
Molecular Mechanisms for the Regulation
of Cancer Cell Biology by Voltage-gated
Sodium Channels and Comparison with
Non-excitable and Non-cancer Cells
Important questions still remain: how can NaVα activity,
through a persistent entry of Na+, be responsible for the
increased invasiveness observed in cells that do not trigger action
potentials? And what are the signaling pathways involved? It
is widely known that many intracellular signaling pathways
crucially depend on Ca2+ ions for which a myriad of Ca2+-
sensitive proteins exist. Could it be the same for Na+ ions?
The way by which NaV activity controls cancer cell invasiveness
remained unknown for long and is still unclear despite the recent
advances that have been done and will be discussed later on.
In order to understand a possible signaling pathway that could
be under the control of NaV activity, but independent of action
potential generation, we will give a rapid overview of the current
knowledge on the physiological participation of NaV channels
in non-excitable cells. We will compare this to NaV-dependent
mechanisms that have been identified in cancer cells.
Normal Expression and Non-excitable Roles of
Nav in Non-cancer Cells
Sodium channels, especially NaVα proteins, have been found
in many cell types not described for the generation of action
potentials, such as in epithelial gastric cells (Wu et al., 2006) in
which NaV1.5 participates to the control of cell proliferation,
in astrocytes in which the same channel participates to cell
migration (Pappalardo et al., 2014), in macrophages and
microglial cells in which NaV1.6 channel regulates the phagocytic
capacity (Craner et al., 2005; Black and Waxman, 2012) and
NaV1.5 participates to the endosomal acidification (Carrithers
et al., 2007, 2009), or in dendritic cells in which NaV1.7
maintains the membrane potential and regulates the activation
and chemokine-induced migration (Kis-Toth et al., 2011). NaVα
have been characterized to be expressed both at the plasma
membrane and in intracellular compartments of many other
cell types, and the hypothesis has emerged that they could
physiologically play non-excitable roles (for a recent review,
see Black and Waxman, 2013). It is very interesting to note
the recurrent participation of NaV channels in normal cell
migration/invasiveness, phagocytosis, endosomal acidification,
and podosomal activities, that are cellular properties over-
activated in cancer cells and often associated with aggressiveness
(Brisson et al., 2012) (see Figure 1).
Non-excitable roles of NaV channels in cell migration and
proliferation during embryogenesis and tissue repair could be
relevant to explain similar phenomena in cancer cells. They will
be briefly described thereafter.
Sodium Channels and the Regulation of Ca2+
Concentration in Smooth Muscle and other Cells
Sodium currents have been measured in many primary-cultured
smooth muscle cells from human pulmonary arteries (James
et al., 1995), human coronary arteries (Quignard et al., 1997),
mesenteric arteries (Berra-Romani et al., 2005), or from aortic
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FIGURE 1 | NaVα promotes carcinoma cell invasiveness and
metastatic progression. Normal epithelial cells are morphologically and
functionally polarized (apico-basal polarization). They are tightly connected
together by different cell junctions such as tight junctions, adherens
junction, gap junctions, and desmosomes. They are associated to the
basement membrane by hemidesmosomes composed of integrins. They
are maintaining a particular organization of the cytoskeleton. Particularly,
actin filaments (F-actin) form a cortical network under the plasma
membrane that is determinant in keeping this polarized morphology.
During the carcinogenetic process, cancer cells that survived to
environmental constraints, and have been selected, have acquired
multiple mutations conferring proliferative and immortality advantages. This
process is responsible for the development of a primary in situ tumor that
becomes invasive when some aggressive cancer cells gain the ability to
degrade and migrate through the extracellular matrix (ECM). This second
step is critical for invasive cancer cells to reach the blood circulation and
eventually to colonize and form secondary tumors (metastases) in distant
organs. Migrative cancer cells have lost their intercellular junctions, their
apico-basal polarization and now display a front-rear polarization. The
proteolysis of the ECM by cancer cells is dependent on the formation
and activity of protrusive structures, enriched in F-actin, called
invadopodia. All these changes in cell phenotype and behavior are
obtained through the process called Epithelial-to-Mesenchymal Transition
(EMT). NaVα proteins are abnormally expressed in highly invasive cancer
cells, and are found in invadopodia (see magnification). They are
co-localized with Na+-H+ exchangers type 1 (NHE-1) for which they
enhance the protons extrusion activity. This leads to a peri–invadopodial
acidification favorable to the activity of acidic cysteine cathepsins,
released by cancer cells, and consequently to the ECM degradation.
NaVα proteins are also proposed to increase the intracellular Ca
2+
concentration through the participation of Na+-Ca2+ exchangers (NCX).
NaVα activity, through a persistent window current, sustains Src kinase
activity, the phosphorylation (Y421) of the actin nucleation-promoting
factor cortactin, and the polymerization of actin filaments. Altogether, this
suggests that NaVα activity in cancer cells enhances both the formation
and the ECM degradative activity of invadopodia.
arteries (Cox et al., 1998). These smooth muscles cells are not
excitable (if one considers excitability as the capacity to produce
action potentials) and at least one of their primary roles has been
unraveled in rat aorta (Fort et al., 2009). Large arteries such as
the aorta do not show action potentials but rather display small
variations in their membrane potential. A depolarization as small
as 10mV has been shown to increase the vascular tone. This was
prevented by the use of 1µM TTX. The hypothesis put forward
by the authors was that the increase in the intracellular sodium
concentration in turn induced an entry of calcium, through the
sodium-calcium exchanger (NCX), which was responsible for the
increase in cell contraction (Fort et al., 2009). It has never been
tested whether NaV activity could also regulate smooth muscle
cell proliferation in physiological, or even in pathophysiological
conditions such as in pulmonary hypertension. Nevertheless, this
mechanism of action resembles that found for NaV channels
expressed in NG2 oligodendrocyte progenitor cells. In these
cells, the stimulation of GABAA receptors induced a membrane
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depolarization activating NaV channels. These channels were
responsible for a non-inactivating INa, leading to an increased
intracellular Ca2+ concentration and an enhanced cell migration
due to the reverse mode functioning of NCX-1, (Tong et al.,
2009). A similar mode of action was recently published for
astrocytes migration in astrogliosis (Pappalardo et al., 2014).
Sodium Channels in Cardiac and in Neuron Cells
during Embryogenesis
It is well-known that the sodium current (Weidmann, 1961) due
to the activity of NaV1.5 is responsible for the excitability of
cardiac cells. However, a careful examination of the expression of
NaV channels during cardiac development suggests that NaV1.5
is also involved in the development of the heart independently of
the generation of action potentials. Indeed, it has been reported in
mice that a homozygous deletion of the cardiac sodium channel
gene SCN5A resulted in the death of embryos at the age of 10.5
days, before a large sodium current can be seen (Davies et al.,
1996; Papadatos et al., 2002). Embryos had small ventricles, but
had intact endocardial tissues and vasculature (Papadatos et al.,
2002). Similar observations have been seen in zebrafish embryos
(Chopra et al., 2010). These authors observed that the heart
tube of zebrafish lacking the ortholog gene SCN5Lab (one of
the two orthologs of the SCN5A gene) had less cardiomyocytes
than the wild type zebrafish 24 h after fertilization, and that the
embryos died before 5 days post-fertilization. Later on, Bennett
and collaborators demonstrated that the NaV channel expressed
by the SCN5Lab gene is required for the specification of the pre-
cardiac mesoderm, and for the proliferation and growth of the
developing heart (Bennett et al., 2013). The precise mechanism
of action is not yet understood but these authors underlined that,
as an integral component of cardiomyocytes, NaV could serve
non-electrogenic roles by interacting withmany partner proteins.
Interestingly, NaV channels appear to have critical non-
excitable roles during embryogenesis. This was also identified
during neuronal embryogenesis in mouse neocortex. Indeed,
long before synaptogenesis, the early expression and function of
NaV have been involved in neuronal development and in the
colonization of the neocortex by pioneer neurons originating
from the preplate. It was showed that preplate neurons of the
mouse neocortex express functional NaV1.3 as early as day 12 of
embryonic development, and that the activity of the channel was
not related to cell excitability (Albrieux et al., 2004). This channel
was proposed to increase the intracellular concentration of Ca2+
through the participation of the NCX exchanger, thus triggering
Ca2+-dependent signaling in the preplate neurons, leading to
glutamate secretion and the development of the neocortex before
functional synapses are formed (Platel et al., 2005).
Sodium Channels in Tissue Regeneration
A very exciting study came from the group of Levin, working
on the regeneration of an entire organ in Xenopus laevis larvae
(Tseng et al., 2010). It is known that during embryogenesis,
amphibians can regenerate and restore amputated, complex
organs, containing different cell types such as those constituting
muscles, peripheral nerves, vasculature, skin, etc. The authors of
this study demonstrated that NaV1.2 expression and activity was
critical for tail regeneration. The expression of SCN2A gene was
up-regulated 18 h after tail amputation. Such a transcriptional
regulation of SCN2A seemed to occur after the membrane
hyperpolarization mediated by the activity of the H+ pump
V-ATPase. The use of siRNA or pharmacological tools to
inhibit NaV1.2 expression or activity, respectively, prevented
regeneration. On the contrary, the use of the sodium ionophore
monensin, or the heterologous expression of human NaV1.5
in NaV1.2 knocked-out embryos were capable to restore tail
regeneration. The sodium influx was therefore demonstrated
to be critical and further identified as being responsible for
activating downstream signaling such as the BMP and Notch
pathways (Tseng et al., 2010).
Whether the modulation of the intracellular Ca2+
concentration is involved or not in this effect is not known.
However, this study clearly highlights the role of intracellular
Na+ as an important regulator of multiple signaling pathways at
least in functions that appear relevant to the physiopathology of
cancer.
Current Hypotheses on Cellular Mechanisms by
which Nav Channels Expressed in Cancer Cells
Promote Invasiveness
The acquisition of an increased invasive capacity by cancer
cells is a critical step in primary tumor growth and obviously
in the development of metastases, especially in the case of
carcinomas. What is known is that cancer cell invasiveness
initially depends on the epithelial-to-mesenchymal transition
(EMT), a process by which epithelial cancer cells lose their apico-
basal polarity, cell-cell adhesion capacity, and gain migratory and
invasive properties. Aggressive cancer cells are more invasive,
owing to their ability to digest and to migrate through the
extracellular matrix (ECM) (Gupta and Massague, 2006; Friedl
and Alexander, 2011). Cancer cell motility relies on molecular
mechanisms, such as the nucleation and polymerization of
actin at the cell front, actomyosin contractility, and cycles of
formation and disruption of focal adhesions. These mechanisms
lead to the formation of lamellopodia at the cell front and the
adhesion-mediated traction of the cell. All these properties are
orchestrated by Rho guanosine triphosphate hydrolases and their
associated signaling pathways (Friedl and Brocker, 2000; Ridley
et al., 2003). The ECM proteolysis is performed through the
activation of proteases, such as the matrix metalloproteinases
(MMPs) or membrane-bound MMPs (MT-MMPs) (Egeblad and
Werb, 2002) or the cysteine cathepsins (Jedeszko and Sloane,
2004; Mohamed and Sloane, 2006; Gillet et al., 2009), at the
extracellular side of specialized structures of invasive cancer cells,
protrusive into the ECM, and called invadopodia (Linder, 2007).
The tumor microenvironment is also a determinant in cancer
cells dissemination. Particularly, the extracellular compartment
of tumors is known to be more acidic than the extracellular space
of normal tissues (pH 6.2-6.8 instead of pH 7.2-7.4), owing to
the selection, under hypoxic tumor conditions, of cancer cells
having a preponderant glycolytic metabolism. Surprisingly, these
cancer cells keep this preferred metabolism even in normoxic
conditions, a condition called the “Warburg effect” which is
associated with the intense eﬄux of metabolically-produced H+
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in order to maintain the intracellular pH (pHi) (Cardone et al.,
2005; Kroemer and Pouyssegur, 2008). The eﬄux ofH+ generates
the extracellular acidification that potentiates cell migration
(Stock and Schwab, 2009) and enhances the degradation of the
ECM for cancer cell dissemination (Cardone et al., 2005). Among
all pH regulators, the Na+/H+ exchanger type 1 (NHE1) has
drawn a lot of attention because it is overexpressed and over-
activated in cancer cells (Gatenby et al., 2007), and its activity
is associated with cancer cell survival, migration and metastatic
progression (Cardone et al., 2005; Brisson et al., 2012). NHE1 was
recently found to be localized in breast cancer cell invadopodia
and to modulate both their formation and proteolytic activity
(Frantz et al., 2007; Busco et al., 2010).
As detailed previously, NaVα are abnormally expressed in
cancer cells, especially from epithelial origins, while they are
not expressed in non-cancer tissues, and it is proposed that
their function is associated with cancer progression (Roger et al.,
2006; Brackenbury, 2012). Most of the mechanistic details have
been obtained in breast cancer cells so far. Importantly, the
expression of the NaV1.5 isoform in breast tumors, under the
form of a neonatal splice variant called nNaV1.5, is associated
with metastases development and patients’ death (Fraser et al.,
2005; Yang et al., 2012a). In highly aggressive human breast
cancer cells, the activity of NaV1.5 is not associated with the
triggering of action potentials. It enhances ECM degradation
and cancer cell invasiveness by increasing the activity of
extracellular acidic cysteine cathepsins B and S (Roger et al.,
2003; Gillet et al., 2009). Cancer cell invasion is reduced
by shRNA targeting the expression of NaV1.5, as well as by
inhibitory molecules that plug and close the internal pore of
the NaV channel, such as tetrodotoxin, or reduce its activity
such as ranolazine (Driffort et al., 2014). On the contrary,
ECM invasion is increased by drugs that increase NaV activity,
such as veratridin (Gillet et al., 2009). Altogether, these results
demonstrated the importance of NaVα channel activity, through
a persistent window current and suggested the participation of a
Na+-dependent signaling. NaV-dependent invasiveness has been
shown to be mediated through the participation of NHE1 and the
subsequent acidification of the pericellular microenvironment
(Gillet et al., 2009; Brisson et al., 2011). NHE1 and NaV1.5
proteins can be co-immunoprecipitated and were proposed to
form functional complexes located in caveolin-1-containing lipid
rafts, and more specifically in invadopodia (Brisson et al., 2011,
2013). How NaV1.5 activity modulates NHE1 is unclear, and
was initially counterintuitive as both transporters are expected
to induce an entry of Na+ that would tend to slightly decrease
the sodium gradient used as a fuel by NHE1 to extrude protons
(See Figure 1). Therefore, even though it is very unlikely that
the sodium gradient would be reversed, even in some subcellular
microdomains, it could have been initially thought that NaV
activity would reduce the activity of NHE1. Instead, NaV1.5 was
responsible for the allosteric modulation of the NHE1 exchanger,
FIGURE 2 | NaVα proteins control the intracellular concentration of
Na+, a second messenger that could control normal and cancer
cell migration and invasiveness. NaVα proteins allow the entry of Na
+
into the cell. This entry of cations is known to depolarize the membrane
potential (Vm) and to initiate action potentials in excitable cells. NaVα
proteins also controls the intracellular concentration of Na+ that could be
considered as a second messenger since it regulates, directly or
indirectly, many signaling pathways involved in cell polarity, cell migration,
and extracellular matrix (ECM) remodeling. These properties are involved
in physiological cell migration and invasiveness, such as in organogenesis
and tissue repairing and also in the pathological migration and
invasiveness of cancer cells.
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rendering it more active for the extrusion of H+ at pHi values
between 6.4 and 7.Moreover, NaV1.5 activity sustained Src kinase
activity, the phosphorylation of the actin-nucleation promoting
factor cortactin on tyrosine 421, the polymerization of the F-
actin cytoskeleton and the adoption by cells of a spindle-shaped
elongated morphology (Brisson et al., 2013). Altogether, these
results indicated a prominent role of NaV1.5 in both invadopodial
formation and proteolytic activity, and its participation to
“mesenchymal invasion” (Figure 1).
One working hypothesis is that the Na+ cation, by itself,
is responsible for the allosteric modulation of NHE1 and the
activation of members of the Src kinase family through a not
yet identified Na+-dependent signaling pathway. Alternatively,
NaV activity could also induce local changes in intracellular Ca
2+
concentration, possibly through NCX exchangers, which in turn
could modulate the activity of NHE1, known to be modulated by
intracellular Ca2+ through the binding of calmodulin to an IQ
motif in its C-terminus (Li et al., 2013). These aspects will have to
be further studied.
In two recent studies, performed by the group of Brackenbury
and ours, it was clearly demonstrated that the expression
of NaV1.5 in human breast cancer cells is critical for the
metastatic colonization of lungs of immunodepressed mice,
and that inhibitors of NaV1.5 that are approved by the Food
and Drug Administration (FDA), such as ranolazine for the
treatment of chronic angina, or phenytoin as an anticonvulsant,
significantly reduced metastatic organ colonization by NaV1.5-
expressing human breast cancer cells (Driffort et al., 2014;
Nelson et al., 2015). These results certainly open new therapeutic
opportunities in which conventional inhibitors of NaV channels,
already approved for other clinical use such as antiarrhythmic,
anticonvulsant, or anesthetic drugs could be repurposed for
the prevention and/or reduction of metastatic spreading from
primary tumors.
Conclusions
There is growing evidence that the occurrence of metastatic
carcinomas is associated with the abnormal expression of NaV.
Several different NaVα have been particularly identified such
as NaV1.5, NaV1.6, and NaV1.7. Not only are these proteins
expressed but they are also active, giving rise to sodium
currents which appear to be influential for the regulation of
invasive properties, in a manner that is most likely independent
of the generation of action potentials. While the protein is
important, its Na+ permeation might be the key parameter
controlling signaling pathways of the mesenchymal invasion,
through the regulation of different other proteins such as NHEs
or NCXs. Interestingly, there is also new evidence indicating
that NaVα are involved in the development and regeneration
of organs during embryogenesis through pathways that are
independent of membrane excitability. These results suggest
that NaV proteins may have many physiological roles. They
might represent important regulators of the sodium homeostasis
being involved in more cellular properties than the sole control
of the membrane potential, and that will have to be further
studied.
If we postulate that in cancer, the abnormal expression of
proteins is the consequence of the re-expression of a fetal
or neonatal phenotype, it is likely that NaV were involved
in the initial migration and invasiveness of cells during
the development of organs. If so, this suggests that during
development of organisms, NaV may have different roles: a
primary role in embryogenesis and organogenesis independent
of cell excitability of not yet differentiated cells, and secondarily
in the generation of action potentials and rapid cell-cell
electrochemical communications in well-differentiated cells such
as nerve or muscle cells. Eventually, we propose that Na+ ions
are important second messengers that are finely regulated in time
and intracellular concentration in normal cells, and deregulated
in the cancer disease (Figure 2).
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